Connection

Co-Authors

This is a "connection" page, showing publications co-authored by IGNACIO IVAN WISTUBA and MARIA DEL CARMEN BEHRENS.
  1. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer. 2021 05; 22(3):e415-e424.
    View in: PubMed
    Score: 0.766
  2. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65.
    View in: PubMed
    Score: 0.482
  3. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res. 2010 Jan 01; 16(1):34-44.
    View in: PubMed
    Score: 0.371
  4. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61.
    View in: PubMed
    Score: 0.126
  5. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92.
    View in: PubMed
    Score: 0.124
  6. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013 Nov 15; 19(22):6261-71.
    View in: PubMed
    Score: 0.120
  7. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1747-1754.
    View in: PubMed
    Score: 0.114
  8. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila). 2013 Jan; 6(1):8-17.
    View in: PubMed
    Score: 0.113
  9. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40.
    View in: PubMed
    Score: 0.109
  10. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res. 2011 Sep 01; 17(17):5705-14.
    View in: PubMed
    Score: 0.103
  11. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21.
    View in: PubMed
    Score: 0.103
  12. Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):217-23.
    View in: PubMed
    Score: 0.100
  13. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011 Apr 15; 17(8):2434-43.
    View in: PubMed
    Score: 0.100
  14. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010 Jul 15; 16(14):3743-53.
    View in: PubMed
    Score: 0.096
  15. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010 Feb 09; 5(2):e9112.
    View in: PubMed
    Score: 0.093
  16. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep 01; 15(17):5359-68.
    View in: PubMed
    Score: 0.091
  17. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009 Aug 01; 15(15):4829-37.
    View in: PubMed
    Score: 0.090
  18. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009 May; 22(5):668-78.
    View in: PubMed
    Score: 0.088
  19. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6014-22.
    View in: PubMed
    Score: 0.085
  20. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Jan 01; 14(1):41-7.
    View in: PubMed
    Score: 0.081
  21. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006 Dec 01; 107(11):2637-46.
    View in: PubMed
    Score: 0.075
  22. Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3615-9.
    View in: PubMed
    Score: 0.060
  23. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev. 2000 Oct; 9(10):1027-35.
    View in: PubMed
    Score: 0.049
  24. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. Genes Chromosomes Cancer. 2000 Aug; 28(4):359-69.
    View in: PubMed
    Score: 0.048
  25. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000 Jul; 6(7):2604-10.
    View in: PubMed
    Score: 0.048
  26. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000 Apr 01; 60(7):1949-60.
    View in: PubMed
    Score: 0.047
  27. Comparison of molecular changes in cervical intraepithelial neoplasia in HIV-positive and HIV-indeterminate subjects. Gynecol Oncol. 1999 Sep; 74(3):519-26.
    View in: PubMed
    Score: 0.045
  28. Pathogenesis of non-AIDS-defining cancers: a review. AIDS Patient Care STDS. 1999 Jul; 13(7):415-26.
    View in: PubMed
    Score: 0.045
  29. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res. 1999 May; 5(5):991-1000.
    View in: PubMed
    Score: 0.044
  30. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999 Apr 15; 59(8):1973-9.
    View in: PubMed
    Score: 0.044
  31. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 1999 Jan 21; 18(3):643-50.
    View in: PubMed
    Score: 0.043
  32. Molecular abnormalities associated with endocrine tumors of the uterine cervix. Gynecol Oncol. 1999 Jan; 72(1):3-9.
    View in: PubMed
    Score: 0.043
  33. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res. 1998 Dec; 4(12):2931-8.
    View in: PubMed
    Score: 0.043
  34. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA. 1998 May 20; 279(19):1554-9.
    View in: PubMed
    Score: 0.041
  35. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 1997 Sep 17; 89(18):1366-73.
    View in: PubMed
    Score: 0.040
  36. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7779-84.
    View in: PubMed
    Score: 0.034
  37. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Res. 2015 May 15; 75(10):2029-38.
    View in: PubMed
    Score: 0.033
  38. Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Res. 2015 May 01; 75(9):1789-800.
    View in: PubMed
    Score: 0.033
  39. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14788-93.
    View in: PubMed
    Score: 0.032
  40. A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets. Cancer Res. 2014 Sep 01; 74(17):4694-705.
    View in: PubMed
    Score: 0.032
  41. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84.
    View in: PubMed
    Score: 0.031
  42. Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer. Clin Cancer Res. 2014 Mar 15; 20(6):1610-22.
    View in: PubMed
    Score: 0.031
  43. TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. Br J Cancer. 2014 Mar 18; 110(6):1545-51.
    View in: PubMed
    Score: 0.031
  44. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21.
    View in: PubMed
    Score: 0.031
  45. A reevaluation of CD22 expression in human lung cancer. Cancer Res. 2014 Jan 01; 74(1):263-71.
    View in: PubMed
    Score: 0.031
  46. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54.
    View in: PubMed
    Score: 0.031
  47. Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res. 2014 Feb 01; 20(3):595-603.
    View in: PubMed
    Score: 0.030
  48. 19q13-ERCC1 gene copy number increase in non--small-cell lung cancer. Clin Lung Cancer. 2013 Sep; 14(5):549-57.
    View in: PubMed
    Score: 0.029
  49. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3383-95.
    View in: PubMed
    Score: 0.029
  50. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol. 2013 Mar; 8(3):301-8.
    View in: PubMed
    Score: 0.029
  51. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 2013 Mar 15; 19(6):1577-86.
    View in: PubMed
    Score: 0.029
  52. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov. 2013 Apr; 3(4):444-57.
    View in: PubMed
    Score: 0.029
  53. Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle. 2013 Feb 15; 12(4):647-54.
    View in: PubMed
    Score: 0.029
  54. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013 Jan 15; 73(2):571-82.
    View in: PubMed
    Score: 0.028
  55. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep. 2012 Aug 30; 2(2):257-69.
    View in: PubMed
    Score: 0.028
  56. Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol. 2012 Aug; 26(8):1443-54.
    View in: PubMed
    Score: 0.027
  57. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One. 2012; 7(5):e37775.
    View in: PubMed
    Score: 0.027
  58. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32.
    View in: PubMed
    Score: 0.027
  59. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol. 2012 Mar; 137(3):444-50.
    View in: PubMed
    Score: 0.027
  60. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012 Apr 01; 30(10):1129-36.
    View in: PubMed
    Score: 0.027
  61. The role of PKR/eIF2a signaling pathway in prognosis of non-small cell lung cancer. PLoS One. 2011; 6(11):e24855.
    View in: PubMed
    Score: 0.026
  62. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun 01; 118(11):2889-99.
    View in: PubMed
    Score: 0.026
  63. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May 01; 118(9):2454-65.
    View in: PubMed
    Score: 0.026
  64. Activating enhancer-binding protein-2? nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg. 2011 Sep; 92(3):1044-50.
    View in: PubMed
    Score: 0.026
  65. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res. 2011 Jun 15; 71(12):4236-46.
    View in: PubMed
    Score: 0.025
  66. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res. 2011 Jun 15; 17(12):4155-66.
    View in: PubMed
    Score: 0.025
  67. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011 Jun; 152(6):2164-73.
    View in: PubMed
    Score: 0.025
  68. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85.
    View in: PubMed
    Score: 0.025
  69. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2011 Mar 15; 17(6):1490-501.
    View in: PubMed
    Score: 0.025
  70. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 2010 Dec 14; 7(12):e1000378.
    View in: PubMed
    Score: 0.025
  71. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010 Dec 01; 70(23):9937-48.
    View in: PubMed
    Score: 0.025
  72. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res. 2010 Nov 15; 16(22):5522-8.
    View in: PubMed
    Score: 0.024
  73. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol. 2010 Jan; 133(1):133-40.
    View in: PubMed
    Score: 0.023
  74. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila). 2009 Dec; 2(12):1039-49.
    View in: PubMed
    Score: 0.023
  75. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009 Sep 15; 69(18):7439-48.
    View in: PubMed
    Score: 0.023
  76. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009 Aug; 2(8):702-11.
    View in: PubMed
    Score: 0.023
  77. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009 Jul 01; 15(13):4423-30.
    View in: PubMed
    Score: 0.022
  78. Data driven semantic integration of translational lung cancer research at MDAnderson Cancer Center. AMIA Annu Symp Proc. 2008 Nov 06; 927.
    View in: PubMed
    Score: 0.021
  79. A Semantic Web management model for integrative biomedical informatics. PLoS One. 2008 Aug 13; 3(8):e2946.
    View in: PubMed
    Score: 0.021
  80. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res. 2007 Dec 15; 67(24):11630-9.
    View in: PubMed
    Score: 0.020
  81. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006 Dec 01; 66(23):11194-206.
    View in: PubMed
    Score: 0.019
  82. Clonality of combined tumors. Arch Pathol Lab Med. 2002 Apr; 126(4):437-41.
    View in: PubMed
    Score: 0.014
  83. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol. 2001 Dec; 5(6):321-9.
    View in: PubMed
    Score: 0.013
  84. Molecular abnormalities associated with secretory carcinomas of the breast. Hum Pathol. 1999 Dec; 30(12):1435-40.
    View in: PubMed
    Score: 0.012
  85. K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer. 1999 Jul 01; 86(1):14-21.
    View in: PubMed
    Score: 0.011
  86. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 1997 Sep 01; 57(17):3664-8.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.